Welcure Drugs & Pharmaceuticals Ltd in the board of directors meeting held on August 22 has considered and approved Bonus issue and Stock Split. Following company’s stellar Q1FY26 financial results, this move is aimed at enhancing liquidity and broadening shareholding.
1:10 Bonus Issue
The Board has considered and approved issue of Bonus Shares in the ratio of 1:10 (One bonus equity share of Rs. 10 each for every Ten equity share of Rs. 10 each) to the eligible equity shareholders of the Company as on the proposed record date by capitalization of securities premium, subject to the approval of the shareholders of the Company. Total 1,12,35,820 Equity Shares will be issued as Bonus Shares. The bonus shares would be credited within two months from the date of the board approval.
As on 30th June 2025, company has free reserves amounting to Rs. 13.37 crore. Post-bonus issue paid-up share capital: 12,35,94,020 Equity Shares of face value of Rs. 10 each aggregating to share capital of Rs. 123.59 crore. The issuance of Bonus Shares will be issued out of securities premium received in cash and / or free reserve and / or retained earnings of the Company subject to the approval of the Shareholders
10:1 Stock Split
The Board of directors also considered and approved 10:1 stock split. 1 Equity Share of Face Value of Rs. 10 each will be subdivided/split into 10 Equity Shares of Face Value of Rs. 1 each, subject to the approval of Equity Shareholders of the Company through Postal Ballot.
The stock split is aimed at enhancing the liquidity of the Company’s shares in the market and making them more accessible to retail investors. The Record Date for sub-division/split of existing Equity Shares shall be decided after taking aforesaid approval of the Equity Shareholders of the Company. The stock split is expected to be completed within 2 months.
Increase Authorised Share Capital
The Board also considered & approved the Increase in the Authorized Share Capital of the Company from Rs. 186 crore to Rs. 196 crore in the board meeting on August 22 which is subject to the approval of the members.
Excellent Q1FY26 Results –
Recently, the company announced its Q1FY26 financial results. Driven by its strategic foray into fee-based export-oriented sourcing services, company’s Revenue from Operations rose sharply to Rs. 299.91 crore in Q1FY26, up from Rs. 21.21 crore in Q4FY25. This represents growth of around 1300% QoQ. Net Profit surged to Rs. 23.29 crore from Rs. 2.50 crore in Q4FY25, marking an 830% increase.
Previously, the company completed seven export-sourcing assignments totalling Rs. 299.91 crore, earning fixed commission income with no inventory or logistics exposure, maintaining its debt-free status. In addition, a Rs. 517 crore global sourcing mandate from Thailand-based Fortune Sagar Impex Company Limited is expected to generate approximately Rs. 25.85 crore in service income during FY26.
Incorporated in 1992, Welcure Drugs & Pharmaceuticals Ltd is an established pharmaceutical company in India, engaged in the manufacture and trade of a wide range of healthcare formulations. With a focus on quality, compliance, and global integration, Welcure continues to expand its presence in both domestic and international markets.
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Penny stock under ₹15 in focus after board approves 1:10 bonus issue and 10:1 stock split appeared first on Trade Brains.